Why Robotic Cardiac Surgery is Not Reaching Most of the Indian Patients Who Need It

By Dr Nikhil P J Theckumparampil, Cardiothoracic & Vascular Surgeon, Apollo Speciality Hospitals | Monday, 26 October 2026

 Dr Nikhil P J Theckumparampil, Cardiothoracic & Vascular Surgeon, Apollo Speciality Hospitals

India has come a long way in the management of cardiovascular disease. With advances in diagnostics, interventional cardiology and cardiac surgery, patients with complex heart conditions have more options than ever before. However, access to newer surgical technologies is patchy. Robotic-assisted cardiac surgery is one such technology.

This type of technology has been available in India for several years and may provide a minimally invasive option for selected cardiac procedures. By allowing surgeons to operate through smaller incisions with specialised instruments, robotic assistance can potentially reduce surgical trauma and support recovery in appropriately selected patients. Despite these possibilities, robotic cardiac surgery remains concentrated in a limited number of specialised centres and is not yet accessible to a large proportion of Indian patients who may be considered for such procedures.

The question, therefore, is not whether India has access to the technology. It does. The larger challenge is creating the clinical ecosystem required to make it available safely and appropriately to a wider patient population.

Robotic cardiac surgery is not a replacement for conventional surgery. Its role is procedure-specific and depends heavily on patient selection. The nature of the cardiac condition, anatomy, previous surgeries, age, overall health and other medical factors all influence whether a patient is suitable for a robotic approach. In several cases, conventional surgery remains the most appropriate option.

Robotic cardiac surgery is not about adopting newer technology; it is about selecting the right procedure for the right patient to achieve meaningful outcomes

This makes the expertise of the treating team particularly important. A robotic cardiac programme requires more than installing a surgical system. Surgeons need specialised training in robotic techniques, while anaesthetists, perfusionists, nurses and operating-room staff must understand the workflow and technical requirements of these procedures. Critical-care teams also need to be equipped to manage patients after surgery.

Building this experience takes time. Robotic surgery involves a different operating environment from conventional cardiac surgery and teams need to develop familiarity through regular practice. The ability to manage unexpected situations, including conversion to an alternative surgical approach when necessary, is also an important part of maintaining patient safety.

Access to Robotic Cardiac Surgery Beyond Metropolitan Centres

This requirement has contributed to the concentration of robotic cardiac programmes in large metropolitan hospitals. India has a wide network of cardiac centres, but access to highly specialised surgical expertise is not evenly distributed. For a patient living in a smaller city, obtaining an opinion from a robotic cardiac surgeon may require travelling to another State or a major urban centre.

The burden does not end with the operation. Patients and families may have to arrange accommodation, take time away from work and manage postoperative consultations away from home.

For older patients or those with limited family support, these practical considerations may present significant obstacles to pursuing advanced treatment.

Cost is another factor that cannot be overlooked. Robotic programmes require a significant investment in equipment, maintenance, specialised instruments, training and infrastructure. These costs can increase the price of some procedures compared to conventional surgery.

For patients paying a significant part of their healthcare expenses themselves, affordability can influence treatment decisions. At the same time, the economics of surgery should not be judged only by the initial hospital bill. The duration of hospitalisation, time away from employment, rehabilitation and the ability to return to routine activities also affect the overall cost to a patient and family.

Some minimally invasive procedures may offer advantages in terms of recovery, but these outcomes differ between procedures and individuals. They should therefore be discussed as part of an overall treatment assessment rather than presented as automatic benefits of robotic surgery. This is also why patient awareness matters.

Building Clinical Expertise and Patient Awareness

Robotic surgery is increasingly discussed in healthcare, but public understanding of its role in cardiac care remains limited. Patients may associate the word "robotic" with a completely automated operation, when in reality the surgeon remains in control of the procedure. Others may assume that robotic surgery is necessarily better than conventional surgery because it involves newer technology.

A meaningful discussion should explain why a particular procedure is being considered, whether robotic assistance is clinically suitable, what alternatives exist and what the expected recovery may look like. Patients should also be made aware of the experience of the team performing the procedure and the hospital's ability to manage the complete spectrum of cardiac care.

The responsibility for improving access therefore extends beyond hospitals. Referral networks between cardiologists, cardiac surgeons and hospitals can help identify patients who may benefit from assessment at specialised centres.

At present, a patient may undergo several consultations before learning that a minimally invasive or robotic approach could be considered. Greater awareness among referring physicians can help ensure that suitable patients are evaluated earlier, without suggesting that every patient should be directed towards robotic surgery.

Training will be another important part of the next phase of growth. If robotic cardiac surgery is to expand beyond a small number of established programmes, India will need more structured pathways for developing surgical expertise. Simulation-based training, fellowships, mentorship and collaboration between experienced and emerging centres can help build these capabilities.

The expansion of expertise also needs to be accompanied by appropriate standards. Robotic surgery should be integrated into established cardiac-care systems rather than treated as a standalone technology. Centres should have access to imaging, intensive care, emergency support and conventional surgical capabilities so that patient care does not depend on a single technique.

How Can India Expand Access to Robotic Cardiac Surgery?

Digital healthcare may offer another way to reduce some geographical barriers. Remote review of medical records, imaging and investigations can help specialists determine whether a patient needs an in-person evaluation. Tele-consultation cannot replace a detailed clinical assessment, but it can reduce unnecessary travel and help patients reach the appropriate specialist more efficiently.

There is also a need to consider how healthcare financing will evolve. As new technologies become part of clinical practice, insurance coverage and reimbursement frameworks need to keep pace with evidence and appropriate use. Wider access will be difficult if advanced treatment remains financially out of reach for a large section of patients.

However, expanding robotic cardiac surgery should not become an objective in itself. The number of robotic procedures performed is not a measure of progress unless those procedures are being offered to patients for whom the approach is appropriate and are being performed safely.

This distinction is especially important in India. The country continues to face a substantial burden of cardiovascular disease and the priorities of prevention, early diagnosis, risk-factor management, timely referral and access to essential cardiac surgery remain fundamental. Advanced technology should strengthen this continuum of care rather than exist separately from it.

Robotic cardiac surgery should be viewed as one component of India’s evolving cardiac-care landscape. Its value lies in offering appropriately selected patients another surgical option, while conventional surgery and interventional treatments will continue to remain essential.

The onus should be on translating advances in cardiac care into meaningful patient outcomes. For robotic surgery, it would be about creating the expertise, referral pathways and infrastructure to responsibly integrate the technology into routine cardiac care.

“It’s not about the number of robotic systems or procedures. It’s what really matters, which is, are patients getting the right treatment at the right time from the right team?”

            

About the Author:

Dr. Nikhil Pollo Jaik Theckumparampil is a Chennai-based cardiothoracic and vascular surgeon with 10 years of experience. He specialises in minimally invasive cardiac procedures, including TAVR, TMVR, and atrial fibrillation surgery. With advanced surgical training and board certifications from the United States, he brings international expertise to cardiac care, combining innovative surgical techniques with a personalised, patient-focused approach to treatment.

on the deck

Most Viewed

Addressing Antimicrobial Resistance (AMR) Through Collaborative Efforts Fostering a Quality Culture in the Pharmaceutical Industry Advancements in Computer-Aided Drug Design for Pharmaceutical Research Why India is Gaining Popularity for Clinical Trials The Future of Kidney Transplants in India Usage of Conversational AI in the Health Insurance Sector Strategies for India to Reduce Its API Dependence on China Business Impact of USFDA Approvals on Indian Pharma Companies Innovative Strategies for Expanding Access to Life Saving Healthcare Solutions Badhal Village Crisis: How Rapid Diagnostics Could Have Saved Lives Why India is a Hotspot for Biotech Startups? Why Adapting Flexibility in IP Rights will Drive Generics Market Meeting the Challenges of High-Potency API (HPAPI) Production Impact of Human Factors Engineering on Medical Device Safety The Future of Pharma: Embracing Continuous Manufacturing The Role of Orphan Drugs in Treating Rare Diseases Emerging Technologies Shaping the Future of Drug Formulation Strategies for Optimizing Pharmaceutical Supply Chain Efficiency The Future of Medicine: Harnessing the Power of RNA-based Therapeutics AI in Medicine: Unmasking the Myths and Embracing the Transformative Reality Cycle Pharma Acquires Banner Life Sciences WHO's First-ever Global Summit on Traditional Medicine Starts in Gujarat The Importance of Data Integrity in Pharmaceutical Quality Control DCGI in Talks with Stakeholders to Develop a Standardised Web Platform to Assure Drug Quality and Patient Safety Glenmark Pharmaceuticals secures ANDA Nod for 0.03 per cent Tacrolimus Ointment Streamlining Laboratory Operations with a Modern LIMS Healthtech Start-up Suraksha QR Ropes In Actor Murali Sharma as its Brand Ambassador Unlocking the Potential of Pharmacogenomics: Enhancing Drug Safety and Efficacy The Impact of Pharmaceutical Testing on Drug Development India has Identified Three Health Priorities to Strengthen Global Health Infrastructure, says WHO National Health Authority launches 100 Microsites Project to Speed Up Digital Health Adoption India Should Partner with Australia to avail PBS for the Selection, Listing, and Pricing processes of exported drugs, says Sudarshan Jain Zydus Lifesciences India More than Doubles Profit Due to Increased Sales in the US India Triples Organ Donations over Past Decade says Union health minister Mansukh Mandaviya Advent Therapeutics Awarded $3 Million NIH Grant For Novel Neonatal Lung Therapy Three Pharma Marketing Strategies That Drive Sales Novartis Targets India's Rare Disease Market with 17 Clinical Programs UK Health Regulator approves GSK's Vaccine for the common respiratory virus RSV WHO Urges Increased Use Of Recommended Malaria-Fighting Tools Karnataka Budget Offered a Significant Boost to Health & Lifesciences Start-ups with Focus on Infrastructure & Innovation Three High Potential Moonshot Project Areas in Pharma CCI approves Bharat Biotech International-Eastman Exports deal How Biotech is Revolutionizing the Fight Against Cancer LifeCell and HaystackAnalytics ink strategic pact to scale-up TB whole genome sequencing pan-India Mankind Pharma IPO To Open On April 25 With A Price Fixed At Rs 1,026-1,080 Per Share US CDC Approves Second Omicron-Updated COVID Booster For Adults Three Trends that will Impact Pharmaceutical Industry in 2023 ModeX Therapeutics Commences Phase I EBV Vaccine Trial with Merck Designing Impactful Leadership and Talent Management Programs with Strategies for Success Novo Nordisk and Valo Health Partner to develop novel Treatments FOPE Calls for Extended Deadline for Schedule M Compliance Telix Pharma To Acquire ImaginAb to Boost Therapeutics and Innovation Roche Secures US FDA Approval for its Ultra-Sensitive ISH test Rappta Therapeutics and SpringWorks Partner on Molecular Glue Targeting PP2A Taro Pharma To Acquire entire stake in Antibe Therapeutics Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 Emcure Pharma Launches Largest R&D Centre in Ahmedabad Zydus Bags USFDA Nod for Phase II(b) Trial to Optimize Usnoflast Dosage US FDA Approves Amgen's Lumakras-Vectibix Combo for KRAS G12C-Mutated mCRC Glenmark Pharma Unveils generic anticoagulant injectable emulsion Strides Pharma Bags USFDA Nod for OTC Acetaminophen-Ibuprofen Combo Tablets US FDA Lifts Hold on Sanofi's Trial to Make Cialis Available Over-the-Counter Hoth Therapeutics Expands Intellectual Property with New Patents Jaguar Health Starts POC Trial of Crofelemer for Rare Pediatric Disease MVID Pharma and Healthcare Sector Eyes Union Budget 2025 for Innovation Boost How Innovative Drug Formulations are Enhancing Treatment Outcomes Apollo and Mayapada Healthcare Unite to Boost Indonesia's Healthcare Novo Nordisk Reports Positive Phase 1b/2a Results for Amycretin Govt to Extend Schedule M Compliance Deadline for Drug Manufacturers to Dec Lupin Secures US FDA Nod for Ipratropium Bromide Nasal Solution ANDA Granules Pharmaceuticals Secures USFDA Nod for Key Generic Drug Bajaj Healthcare Bags DCGI Nod to Manufacture Pimavanserin API & Formulation Union Budget 2025: Healthcare Gets 9.78% Boost, Allocation Nears 1 Lakh Crore Metropolis & Roche Launch Self-Sampling HPV Test for Cervical Cancer Sigachi Industries Invests $1M in Hyderabad R&D Hub for API Innovation Pharma Testing Market Surges with Rising Demand for Biologics ISTH Releases Clinical Practice Guideline For Haemophilia Treatment Sanofi and Biovac Lead Polio Vaccine Manufacturing Capabilities Sun Pharma and Takeda Ink Pact To Market Gastrointestinal Drug Takeda and Ascentage Pharma Ink Option Agreement For Olverembatinib Enhancing Compliance through Effective Pharmaceutical Regulatory Affairs Strategies India poised to become a Global Hub for Clinical Trials: Exec SCHOTT Pharma Unveils Next-Gen Polymer Syringes for Enhanced Safety GSK's Jemperli Gains EU Nod for First-Line Treatment of Endometrial Cancer Union Health Secretary Urges Stronger Drug Regulations for Quality Control Telangana Govt Inks Landmark Deals to Propel Life Sciences and Job Growth R&D in Indian Pharma: Breakthroughs and Innovations in 2024 Dr. Reddy's Partners with Shanghai Henlius to Develop Cancer Drug Uniphar Expands Global Footprint with Three New Facilities 74th Indian Pharmaceutical Congress 2025 Opens Registrations AGC Pharma Expands HPAPI Capabilities in Barcelona to Meet Growing Demand The Future of Genomic Sequencing: Trends That Will Define the Next Decade Lexaria Bioscience Ethics Review Board Nod to Commence New GLP-1 Study Amitabh Kant Urges India to Focus on Innovation at BioAsia 2025 Government Enhances Research & Integration Initiatives in Unani Medicine Blind & Deaf individuals face Major Barriers to access Medicines: Report C-CAMP and PariSante Campus launched Indo-French Life Sciences Hub Jaguar Health Begins Pediatric Trial for Crofelemer in Short Bowel Syndrome Algiax Pharma Reports Promising Phase 2a Results for AP-325 Govt Bans 34 Antimicrobials for Use in Animals Pharmaceutical Procurement Strategies: How to Optimize Costs Personalized Medicine: Get Tailored Treatment Plans for You Now How to Bridge the Healthcare Gap in Emerging Markets with MedTech The Evolution of In-Vitro Diagnostics: Trends and Future Prospects Needle-Free Injection System: A Game Changer in Less Pain Vaccination How Global Capability Centers are Shaping the Future of Biometrics Building a Successful Pharma Brand in India: The Role of Scientific Communication Unlocking India's Innovation Potential in Pharma The Future of Green Chemistry in API Production Top 10 Pharmaceutical Recruitment Consultants - 2024 | Pharma Outlook Blockchain for Secure Pharmaceutical Supply Chains - 2025 & Beyond Mass Spectrometry in Biomarker Discovery for Early Disease Detection Iconovo and Lonza Team up to Advance Intranasal Biologic with ICOone Nasal Fetal Imaging to Cardiac Diagnosis: The Expanding Role of Ultrasound Balancing Innovation and Affordability in Medical Solutions for India Changing Landscape for LTBI and Syndromic Testing Methodologies How Advanced Training Methods can Enhance Patient Care Balancing Cost Efficiency and Compliance in Pharmaceutical Manufacturing LUB Urges Govt to Scrap Mandatory Lab Testing for Cough Syrup Exports Role of Optical Imaging in Early Cancer Detection and Treatment Hoth Therapeutics Unveils Promising Data for KIT-Targeting Therapy Pharmexcil Engages ASEAN Nations to Boost Pharma Trade Ties Fortis Partners with Teleflex for South Asia UroLift Training Anti-Infectives: How New Research is Shaping Infection Control Building Bridges for Sustainable Growth through Strategic Alliances in Ethical Pharmaceuticals Quality as the Cornerstone of Lab Solutions FDA Approves Roch's NSCLC Diagnostic Linked to Emrelis How Early Detection is Transforming Cancer Treatment in India Ensuring Data Privacy in Pharma World Enhancing Clinical Trial Supply Chain Resilience to Address Global Disruptions in India Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings How Organic Synthesis is Accelerating Drug Discovery in Pharma Strategic finance for pharmaceutical innovation and stability Top 10 Teleradiology Service Providers - 2024 | Pharma Outlook Importance of Investing in R&D and Quality for Competitive Advantage in Eye Care Top 10 In Vitro Diagnostics Companies - 2024 | Pharma Outlook Phytopharmaceuticals: Driving Global Herbal Medicine Innovation Gender Gap in Healthcare: Why Women's Health Needs More Research Impact of Modern Technology on the Indian Life Sciences Sector Why Global Pharma Expects CDMOs to Be Ready for Joint Inspections The Role of Customizable Stent Grafts for Treating Complex Anatomies Nutraceuticals vs Pharmaceuticals: Complementary or Alternative in Chronic Disease Management? Top 10 Pharma CDMO Companies In India – 2023 | Pharma Outlook Leaping Towards Global Compliance with Revised Schedule M Meril Concludes TechVentory, Boosts AI-Driven Healthcare Supply Chains 10 Pharma Sector Revolutions in India Standardizing Medicine Labeling and Embracing Digital Transformation Creating a patient-centric healthcare ecosystem for all Biomanufacturing of Enzymes: A Sustainable Approach to Industrial Biotechnology Integrating CSR into HR Practices to Enhance Brand Reputation in Pharma Merck Launches Phase 3 Trial for Promising Dengue Vaccine V181 Breakthrough: Eye-Opening Healthcare Strategies Doctors Swear By on Doctor's Day 2025 Bristol Myers Squibb Reports Strong Phase 3 Results for Deucravacitinib trail Alcon Launches Innovative Daily Lenses Designed for Long-lasting Comfort Apisolex Excipient by Lubrizol Backs Phase I Drug Success FDA Approves Enflonsia to Prevent RSV in Infants with One Dose Biosimilars in India 2025 Market Trends, Growth Forecast & Opportunities How Regulations Are Shaping India's Medical Device Landscape Bharat Biotech Partners with GSK for Shigella Vaccine Development Eli Lilly Obesity Drug Shows 11.5% Weight Loss in 12 Weeks Laborate Pharmaceuticals: Illuminating Pathways Of Quality, Affordability Innovation In Healthcare Sun Pharma Bags CDSCO Approval to Produce Fexuprazan Hydrochloride Tablets The Fusion of Biology, Medicine, Health, and AI Glenmark Gets DCGI Nod to Launch Oncology Drug BRUKINSA in India Kyndryl Partners with Dr Reddys to Automate Global IT Operations How Robotic Assisted Surgery Is Redefining Precision in Kidney Transplants Top 10 Women Disruptors in Asia Pharmaceutical Industry

Related Articles

© 2026 India Pharma Outlook. All Rights Reserved.